Characteristics of MACE-positive and MACE-negative patients
Features . | MACE-positives . | MACE-negatives . |
|---|---|---|
| No. | 25 | 25 |
| Males/females | 6/19 | 10/15 |
| Median age, y (range) | 48 (18-79) | 54 (22-83) |
| Mean platelet count, × 109/L* | 38 ± 33 | 45 ± 24 |
| 0 to 20 × 109/L, no. (%) | 9 (36) | 5 (20) |
| 21 to 50 × 109/L, no. (%) | 9 (36) | 9 (36) |
| 51 to 100 × 109/L, no. (%) | 7 (28) | 11 (44) |
| Mean duration of disease, mos. (range)* | 40 ± 52 (0.5-169) | 54 ± 39 (0.1-149) |
| Median, mos. | 11 | 51 |
| Less than 6 mos., no. (%) | 9 (36) | 3 (12) |
| Mean ± SD, mos. | 2.3 ± 1.9 | 1.5 ± 1.2 |
| More than 6 mos., no. (%) | 16 (64) | 22 (88) |
| Mean ± SD, mos. | 61 ± 54 | 61 ± 36 |
| Patients on therapy at sampling, no. (%) | 3 (12) | 5 (20) |
| Previous splenectomy, no. (%) | 1 (4) | 2 (8) |
| Previous PC infusion, no. (%) | 2 (8) | 1 (4) |
Features . | MACE-positives . | MACE-negatives . |
|---|---|---|
| No. | 25 | 25 |
| Males/females | 6/19 | 10/15 |
| Median age, y (range) | 48 (18-79) | 54 (22-83) |
| Mean platelet count, × 109/L* | 38 ± 33 | 45 ± 24 |
| 0 to 20 × 109/L, no. (%) | 9 (36) | 5 (20) |
| 21 to 50 × 109/L, no. (%) | 9 (36) | 9 (36) |
| 51 to 100 × 109/L, no. (%) | 7 (28) | 11 (44) |
| Mean duration of disease, mos. (range)* | 40 ± 52 (0.5-169) | 54 ± 39 (0.1-149) |
| Median, mos. | 11 | 51 |
| Less than 6 mos., no. (%) | 9 (36) | 3 (12) |
| Mean ± SD, mos. | 2.3 ± 1.9 | 1.5 ± 1.2 |
| More than 6 mos., no. (%) | 16 (64) | 22 (88) |
| Mean ± SD, mos. | 61 ± 54 | 61 ± 36 |
| Patients on therapy at sampling, no. (%) | 3 (12) | 5 (20) |
| Previous splenectomy, no. (%) | 1 (4) | 2 (8) |
| Previous PC infusion, no. (%) | 2 (8) | 1 (4) |
Mean ± SD.